All In MedTech

Device Trial Radar · NCT04510714

BORIS - aBlação pOR mIcro-ondaS [Microwave Ablation]

A Prospective, Phase III Study to Assess the Efficacy and Safety of Microwave Ablation of Metastatic Lung Sarcoma Lesions.

Last checked: Nov 19, 2026Latest source record: Aug 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 1, 2023

Primary completion

Apr 1, 2025

Study completion Oct 1, 2025

Sponsor

Lead sponsor
Instituto do Cancer do Estado de São PauloAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Angiodynamics, Inc.
First posted
Aug 12, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with sarcoma and lung metastases have few therapeutic options, with poor response to systemic treatment. Many of them are not eligible to surgical treatments due to the high number and distribution of pulmonary lesions or due to comorbidities, which reduce the survival chances of these individuals. Given the high efficacy and overall increased survival demonstrated by recent studies, the minimally invasive treatments (mainly radiofrequency ablation) have gained ground. Although the microwave ablation is a promising new technique for the treatment of patients with pulmonary metastases, there are few studies in the literature to evaluate the efficacy and safety of this procedure in the above population.

Conditions

  • Sarcoma

Interventions

  • Image guided percutaneous microwave ablationDevice

    Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instituto do Câncer do Estado de São Paulo

    São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.